PACIRA BIOSCIENCES, INC. Repayments of Convertible Debt
PACIRA BIOSCIENCES, INC. (PCRX) reported Repayments of Convertible Debt of $192.61 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2022-05-04
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2022-03-31 was $192.61M.
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for the quarter ending 2021-03-31 was $0.00.
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for fiscal 2019 was $338.00K.
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for fiscal 2017 was $118.19M, a 2954725.00% increase from fiscal 2016.
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for fiscal 2016 was $4.00K, a 99.73% decline from fiscal 2015.
- PACIRA BIOSCIENCES, INC. repayments of convertible debt for fiscal 2015 was $1.47M.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 12 month |
|---|---|---|
| 2022-03-31 | $192.61M 10-Q · filed 2022-05-04 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 | |
| 2019-12-31 | $338.00K 10-K · filed 2020-02-21 | |
| 2017-12-31 | $118.19M 10-K · filed 2020-02-21 | |
| 2016-12-31 | $4.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | $1.47M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |